Kerrie Brady, BPharm, MS, MBA

Chief Executive Officer & President

Kerrie Brady brings to OcuTerra Therapeutics her experience as a successful serial biotechnology entrepreneur and strategic business leader with over 30 years of international experience across a variety of therapeutic areas. Prior to joining OcuTerra, Kerrie co-founded Centrexion Therapeutics in 2013 and served as its Chief Business Officer and Executive VP Strategy. As co-founder, she played a key role in growing the initial team from two people to a high-performing 25-person team with five clinical programs. She was instrumental in raising over $150 million in investments, led the $998 million out-licensing deal to Lilly, with over $48 million up front.

Prior to co-founding Centrexion, Kerrie was recruited in 2007 by InterWest Partners to co-found Arcion Therapeutics. As COO, she was key to raising $18 million from venture capital investors and negotiated term sheets for licensing and M&A opportunities. The acquisition of an additional asset resulted in spin-off company, Vallinex, which she led simultaneously with Arcion from 2010 to 2013. As COO at Vallinex, she was instrumental in restructuring the product, securing additional IP, and refocusing its development plan. She structured the startup’s seed funding, negotiated a Series A investment, and organized the company’s acquisition. Kerrie’s entrepreneurial path began in 2006 when she founded Traxion Therapeutics, a boutique biotech company specializing in new drugs that act on ion channels. At Traxion, she built a pipeline of novel early stage assets through in-licensing deals from Japanese pharmaceutical companies.

Kerrie’s earlier career included roles in both biotech (EntreMed, Intracel, Cooperative Research Center for Biopharmaceutical Research) and pharmaceutical organizations (Rhone Poulenc, Farmitalia Carlo Erba) with leadership positions in operations, business development, marketing, and regulatory affairs.

Kerrie holds a BPharm from the Victoria College of Pharmacy, an MBA (Award of Distinction) from the University of Melbourne and an M.S. in Biopharmaceuticals from the University of New South Wales.